Given that the cellular background is critical for determining the function of SS18/SSX fusion protein in human SS, gene expression studies have employed SS18-SSX silencing by siRNA using three SS cell lines and identified genes related to SS18/SSX and several candidates for novel molecular therapy [2, 17]. The gene discussed is SSX2; the disease is synovial sarcoma.